Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

FOXP3/Helios Expression in CD4+ Tcons Correlates With T-Cell Activation After Orca-T in Hematologic Malignancies

February 16th 2025, 5:00pm

Transplantation and Cellular Therapy Meetings

CD4-, FOXP3-, and Helios-positive conventional T cells were increased in patients receiving Orca-T vs peripheral blood stem cell grafts.

Drs Al Malki and Auletta on PTCy GVHD Prophylaxis in Patients With HLA-UUMD

February 15th 2025, 9:45pm

Transplantation and Cellular Therapy Meetings

Monzr Al Malki, MD and Jeffery J. Auletta, MD discuss evaluating PTCy-based GVHD prophylaxis in hematologic malignancies.

Tivozanib Elicits Similar PROs With or Without Nivolumab in Advanced Clear Cell RCC

February 15th 2025, 8:15pm

Genitourinary Cancers Symposium (ASCO GU)

No significant differences in PROs were shown between the tivozanib/nivolumab and tivozanib monotherapy arms in patients with advanced clear cell RCC.

Nivolumab Plus Cabozantinib Provides Durable Benefit in First-Line Advanced RCC

February 15th 2025, 7:58pm

Genitourinary Cancers Symposium (ASCO GU)

Nivolumab in combination with cabozantinib displayed a long-term PFS benefit in patients with treatment-naive advanced RCC.

CBM588 Plus Cabozantinib/Nivolumab Shows Early Activity in Metastatic Renal Cell Carcinoma

February 15th 2025, 7:57pm

Genitourinary Cancers Symposium (ASCO GU)

CBM588 plus cabozantinib and nivolumab shows early efficacy in metastatic renal cell carcinoma.

Cabozantinib Plus Nivolumab/Ipilimumab Sustains PFS Benefit in Advanced RCC

February 15th 2025, 7:53pm

Genitourinary Cancers Symposium (ASCO GU)

Efficacy results remained consistent with previous reports in the cabozantinib, nivolumab, and ipilimumab arm for patients with advanced renal cell carcinoma.

Real-World Data Support the Frontline Use of Avelumab Plus Axitinib in Advanced RCC

February 15th 2025, 7:33pm

Genitourinary Cancers Symposium (ASCO GU)

The combination of first-line avelumab and axitinib was effective and safe in a real-world analysis of patients with advanced RCC.

Updated Data Support Axitinib Interruption and Avelumab Maintenance After Response in Advanced RCC

February 15th 2025, 7:26pm

Genitourinary Cancers Symposium (ASCO GU)

Updated results further supported the feasibility of VEGFR TKI interruption and immunotherapy maintenance in advanced renal cell carcinoma.

Perioperative Lenvatinib Plus Pembrolizumab Is Safe and Effective in Advanced ccRCC

February 15th 2025, 7:10pm

Genitourinary Cancers Symposium (ASCO GU)

Neoadjuvant lenvatinib plus pembrolizumab followed by adjuvant pembrolizumab was safe and effective in patients with locally advanced, nonmetastatic ccRCC.

Lenvatinib Plus Belzutifan Demonstrates Antitumor Activity in Advanced ccRCC

February 15th 2025, 7:04pm

Genitourinary Cancers Symposium (ASCO GU)

Greater responses were observed in a cohort of patients with renal cell carcinoma receiving lenvatinib plus belzutifan vs pembrolizumab plus lenvatinib.

1.34-mg Dose of Tivozanib Is More Efficacious Than Reduced 0.89-mg Dose in RCC

February 15th 2025, 6:36pm

Genitourinary Cancers Symposium (ASCO GU)

An ER model analysis showed that 1.34 mg of tivozanib provided a greater decrease in tumor size and may be more tolerable than an 0.89-mg dose in RCC.

Orca-T’s Display of Decreased NRM, Increased RFS May Contribute to Favorable OS in Hematologic Malignancies

February 15th 2025, 6:19pm

Transplantation and Cellular Therapy Meetings

Orca-T improved OS vs post-transplant cyclophosphamide in a retrospective analysis of patients with hematologic malignancies.

Perioperative Durvalumab Shows Benefits in MIBC Irrespective of pCR Status

February 15th 2025, 4:51pm

Genitourinary Cancers Symposium (ASCO GU)

Data spotlighted that the addition of perioperative durvalumab to radical cystectomy and adjuvant chemotherapy improved outcomes in MIBC.

Dato-DXd Prolongs Responses in Pretreated Advanced/Metastatic Urothelial Cancer

February 15th 2025, 4:35pm

Dato-DXd generated durable responses and produced no new safety signals in patients with heavily pretreated, locally advanced/metastatic urothelial cancer.

Updated Data Reinforce EV-302 Regimen as SOC in Advanced Urothelial Cancer

February 15th 2025, 4:21pm

Genitourinary Cancers Symposium (ASCO GU)

Enfortumab vedotin plus pembrolizumab maintains compelling benefit over chemotherapy in untreated locally advanced or metastatic urothelial cancer.

Orca-Q Shows Promise in High-Risk Hematologic Cancers and BFT Conditioning May Synergize With the Agent

February 14th 2025, 11:06pm

Transplantation and Cellular Therapy Meetings

One-year follow-up data from an ongoing phase 1 study showed that Orca-Q offered similar benefits as T-cell depletion, without the typical compromises seen.

Avelumab Maintenance Improves OS and PFS in Advanced Urothelial Carcinoma, Regardless of Diabetes Status

February 14th 2025, 10:54pm

Genitourinary Cancers Symposium (ASCO GU)

Avelumab first-line maintenance improved survival outcomes in advanced urothelial carcinoma, regardless of diabetes status.

Obe-Cel Elicits High MRD-Negative Response Rates in R/R B-ALL

February 14th 2025, 10:38pm

Transplantation and Cellular Therapy Meetings

MRD-negative remissions with obe-cel were more durable and associated with higher EFS and OS rates vs MRD-positive remissions in relapsed/refractory B-ALL.

Axatilimab Displays Durable Responses in cGVHD Irrespective of Number of Prior Lines of Treatment

February 14th 2025, 10:34pm

Transplantation and Cellular Therapy Meetings

Axatilimab displayed similar efficacy regardless of the number of prior lines of therapy in chronic graft-versus-host disease.

x